On June 14, 2026, Al Majed For Oud Co. announced it has signed a non-binding offer with Othman Abdullah Othman Al-Suwaih, Abdullah Othman Abdullah Al-Suwaih, and Amr Othman Abdullah Al-Suwaih to acquire a target group of companies including Al Safa Pharmaceuticals and Medical Supplies and five other entities across the Gulf region. The parties agreed on an enterprise value of SAR 392 million, subject to adjustment for net debt estimated at approximately SAR 224 million as of December 31, 2025, with consideration to be paid through a combination of cash and new Al Majed For Oud shares valued at SAR 151.01 per share based on 90-day VWAP. The non-binding offer includes a six-month exclusivity period and will terminate if a binding acquisition agreement is not executed within six months, with the transaction subject to regulatory approvals and shareholder approval for any capital increase.

Original announcement:

Important Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.